Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
A systematic review of matched cohort and case-control studies was performed to examine the mortality attributable to candidemia. The review included studies that compared mortality of patients with candidemia (cases) to that of matched patients without candidemia (controls). Secondary variables examined were the length and cost of hospital stay. Relevant studies were identified using the PubMed database and by examining the references of the initially selected studies. Two independent reviewers performed the literature search, study selection and data extraction from the identified studies. A total of seven studies were included in the review. The patients included those hospitalized in intensive care units (ICU) and hospital wards and those undergoing transplantation. The mortality attributed to candidemia in the reviewed studies ranged from 5 to 71%. For six of the reviewed studies the difference in mortality between cases and controls was statistically significant. Among those who survived, the length of stay and the cost of hospitalization of patients with candidemia were significantly higher than those of controls. Despite the methodological heterogeneity of the reviewed studies, the data from the available matched cohort and case-control studies suggest that candidemia is associated with considerable mortality that is attributed, at least to some degree, to the infection itself and not only to the presence of another comorbidity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estimates of mortality attributable to candidemia range from 5% to 71%, varying based on setting, age group, and study design [10].”
From Burden of Candidemia in the United States, 2017 (2020) · cites this paper as [10]
In the citing paper
“The mortality attributed to candidemia, in the reviewed studies, ranged from 5 to 71%, and for six, the difference in mortality between cases and controls was statistically significant.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [14]
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 1×
“It should be noted, as also stated by the authors of the study, that this definition is not in accordance with the Infectious Diseases Society of America (IDSA) guidelines for treatment of candidiasis [19]; these consider treatment for candidemia adequate if amphotericin B, fluconazole or caspofungin continues for 2 w…”
ResultNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 1×
“This is also stressed in other articles [17, 18].”
ResultSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 8×
“It is also interesting that when the results were analyzed using matched-pair analysis, the difference between cases and controls in the median number of days spent in hospital was further augmented [12, 13].”
BackgroundResultInfluential(1999) · American Journal of Infection Control · doi:10.1016/s0196-6553(99)70031-3 · Cited by 901
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831 · cited 8×
“[13] performed matching according to disease severity.”
BackgroundResultInfluentialZaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784 · cited 7×
“length of hospital stay of adult cases was more than double that of controls [10].”
BackgroundMethodResultInfluential
Cited by
Items 101–200 of 293
Doğan, Ö., Yesilkaya, A., Menekşe, Ş., Güler, Ö., Karakoç, Ç., Çınar, G., Kapmaz, M., Aydın, M., Keske, Ş., Şahin, S., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105992 · Cited by 38
Effects of candidaemia on outcome of burns
Vinsonneau, C., Benyamina, M., Baixench, M.-T., Stéphanazzi, J., Augris, C., Grabar, S., Paugam, A., & Wassermann, D. (2009) · Burns · doi:10.1016/j.burns.2008.05.028 · Cited by 36
How to select an antifungal agent in critically ill patients
Dimοpoulos, G., Antonopoulou, A., Armaganidis, A., & Vincent, J. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2013.04.006 · Cited by 35
“The cited attributable mortality for Candida infections varies from 5% to 71% [6].”
BackgroundZheng, Y., Xie, T., Wu, L., Liu, X.-Y., Zhu, L. Y., Chen, Y., Mao, E., Han, L., Chen, E., & Yang, Z. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00441-y · Cited by 34
Araújo, R., Carneiro, A., Costa‐de‐Oliveira, S., Pina‐Vaz, C., Rodrigues, A. G., & Guimarães, J. E. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01034.x · Cited by 37
Candida Infections and Modelling Disease
MacCallum, D. M. (2009) · Springer eBooks · doi:10.1007/978-3-642-03150-2_3 · Cited by 33
Giacobbe, D. R., Esteves, P., Bruzzi, P., Mikulska, M., Furfaro, E., Mesini, A., Tatarelli, P., Grignolo, S., Viscoli, C., Colombo, A. L., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.06.002 · Cited by 35
Candida profiles and antifungal resistance evolution over a decade in Lebanon
Araj, G. F., Asmar, R. G., & Avedissian, A. Z. (2015) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.6550 · Cited by 33
“infections, especially Candida infections [1-4].”
Dimοpoulos, G., Velegraki, A., & Falagas, M. E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01368-08 · Cited by 35
“Candidemia occurs in up to 10% of the patients in intensive care units (ICU), leading to prolonged use of mechanical ventilation and duration of hospital stay (5, 7, 8, 14, 16).”
BackgroundSelf-citationPitarch, A., Jiménez, A., Nombela, C., & Gil, C. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200780039 · Cited by 35
Risk Factors for Voriconazole‐Associated Hepatotoxicity in Patients in the Intensive Care Unit
Wang, Y., Wang, T., Xie, J., Yang, Q., Zheng, X., Dong, W., Xing, J., Wang, X., & Dong, Y. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1779 · Cited by 30
Metwally, L. A., Walker, M. J., Coyle, P. V., Hay, R. J., Hedderwick, S. A., McCloskey, B. V., O’Neill, H. J., Webb, C. H., & McMullan, R. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.04.003 · Cited by 31
Coping with Candida Infections
Evans, S. E. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200907-075al · Cited by 32
“A recent systematic review identified the attributable mortality for invasive candidiasis to be between 5 and 71% (8), with expert opinion suggesting the actual figure to be around 15 to 25% for adults (1).”
BackgroundEmerging Role of Candida in Deep Sternal Wound Infection
Modrau, I. S., Ejlertsen, T., & Rasmussen, B. S. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.08.012 · Cited by 35
Samonis, G., Kofteridis, D. P., Saloustros, E. S., Giannopoulou, K., Ntziora, F., Christidou, A., Maraki, S., & Falagas, M. E. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701765657 · Cited by 33
Self-citationKhan, Z., Mustafa, A. S., & Alam, F. F. (2009) · PubMed · Cited by 28
Increased susceptibility to Candida infection following cecal ligation and puncture
Davis, C. G., Chang, K. C., Osborne, D., Walton, A. H., Dunne, W. M., & Muenzer, J. T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.09.017 · Cited by 33
Role of protein phosphomannosylation in the Candida tropicalis–macrophage interaction
Hernández-Chávez, M. J., Franco, B., Clavijo-Giraldo, D. M., Hernández, N. V., Estrada-Mata, E., & Mora-Montes, H. M. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/foy053 · Cited by 30
Usher, J., & Haynes, K. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008259 · Cited by 27
“Systemic fungal infections are currently very difficult to diagnose, and even with best practice management mortality rates are generally higher than for bacterial disease [11].”
BackgroundTeo, J. Q.-M., Candra, S. R., Lee, S. J.-Y., Chia, S. Y.-H., Leck, H., Tan, A., Neo, H.-P., Leow, K. W.-L., Cai, Y., Ee, P. L. R., et al. (2017) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-017-0184-1 · Cited by 27
“The crude mortality is high, ranging from 30–50% [2–4]; while the attributable mortality due to candidemia varied from 15–49% [5, 6].”
BackgroundContinuous versus Conventional Infusion of Amphotericin B Deoxycholate: A Meta-Analysis
Falagas, M. E., Karageorgopoulos, D. E., & Tansarli, G. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077075 · Cited by 29
“IFIs are characterized by high mortality, [10,11,12] while most occur in patients with hematologic malignancies, transplant”
BackgroundSelf-citationZhang, L., Wang, H., Xiao, M., Kudinha, T., Mao, L.-L., Zhao, H.-R., Kong, F., & Xu, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114004 · Cited by 28
“Invasive candidiasis is now widely recognized as an important public health problem, with considerable morbidity, mortality, and associated health care costs [1–3].”
BackgroundPiqueras, A., Ganapathi, L., Carpenter, J. F., Rubio, T. T., Sandora, T. J., Flett, K. B., & Köhler, J. R. (2021) · Journal of Fungi · doi:10.3390/jof7020078 · Cited by 33
Han, S., Yim, J., Yoo, C., Kim, Y. W., Han, S. K., Shim, Y.-S., & Lee, S. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.5.671 · Cited by 32
Invasive Candida Infections in the ICU: Diagnosis and Therapy
Hankovszky, P., Társy, D., Öveges, N., & Molnár, Z. (2015) · The Journal of Critical Care Medicine · doi:10.1515/jccm-2015-0025 · Cited by 31
“Recent studies indicate it varies between 40-60% [10-12] and within certain conditions mortality can reach 100% [5].”
BackgroundAtilla, A., Doğanay, Z., Çelik, H. K., Demirağ, M. D., & Kılıç, S. (2017) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1511-29 · Cited by 27
“reported a systematic review of matched cohort studies in which the attributable mortality rates ranged from a nonsignificant 5% to a dramatic 71%, with six out of seven studies finding significantly higher mortality among case patients (27).”
BackgroundJekarl, D. W., Lee, S., Lee, S., Park, Y.-J., Lee, J., Baek, S. M., An, Y. J., Ock, S. M., & Lee, M. (2012) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21535 · Cited by 25
“Candidemia is associated with ICU and hospital stays and has variable mortality from 5% to 71% (10).”
BackgroundManagement ofCandidainfections in the adult intensive care unit
Cruciani, M., & Serpelloni, G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.175 · Cited by 34
“Crude mortality rates have been estimated in the range 25 – 75% depending on patient age and severity of underlying disease, and the attributable mortality of candidaemia has been estimated to be 5 – 71% [13,14,27-31] .”
BackgroundFungal Infections in COVID-19 Intensive Care Patients
Coşkun, A. S., & DURMAZ, Ş. Ö. (2021) · Polish Journal of Microbiology · doi:10.33073/pjm-2021-039 · Cited by 30
Ibrexafungerp: A narrative overview
Ayoubi, L. W. E., Allaw, F., Moussa, E., & Kanj, S. S. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100245 · Cited by 41
“It is characterized by a high mortality rate, reported to be as high as 70 % in bloodstream infections (Falagas et al., 2006).”
BackgroundImproving patient care through implementation of an antimicrobial stewardship program
Palmer, H. R., Weston, J. S., Gentry, L. O., Salazar, M. J., Putney, K. S., Frost, C. P., Tipton, J. A., Cottreau, J. M., Tam, V. H., & Garey, K. W. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100635 · Cited by 24
“Despite the availability of potent antifungals, the rates of mortality attributable to candidemia vary widely (4–71%).(18) On many occasions, the CASE team noted that patients with positive Candida cultures were not receiving antifungal therapy until days after identification of the organism.”
BackgroundReboli, A. C., Rotstein, C., Kett, D. H., Maschio, M., Cartier, S., Chambers, R. B., & Tarallo, M. (2011) · PharmacoEconomics · doi:10.2165/11584810-000000000-00000 · Cited by 26
Épidémiologie des candidémies : étude observationnelle prospective d’un an dans l’Ouest de la France
Talarmin, J. P., Boutoille, D., Tattevin, P., Dargère, S., Weinbreck, P., Ansart, S., Chennebault, J. M., Hutin, P., Leautez-Nainville, S., Gay‐Andrieu, F., et al. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.02.008 · Cited by 32
Infection control measures to prevent hospital transmission of candida
Türe, Z., & Alp, E. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1510282 · Cited by 28
“The mortality attributed to candidemia is ranged from 5% to 71% [6].”
BackgroundCampigotto, A. J., Richardson, S. E., Sebert, M., McElvania, E., Chakravarty, A., & Doern, C. D. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00578-16 · Cited by 23
Molecular investigation of a fungemia outbreak due to Candida parapsilosis in an intensive care unit
Dizbay, M., Kalkancı, A., Sezer, B. E., Aktaş, F., Aydoğan, S., Fidan, I., Kuştımur, S., & Sugita, T. (2008) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702008000500010 · Cited by 30
“Candidemias have been found to be associated with increasing mortality, length of hospital stay and hospital costs [2,3].”
BackgroundInitial antifungal strategy does not correlate with mortality in patients with candidemia
Murri, R., Scoppettuolo, G., Ventura, G., Fabbiani, M., Giovannenze, F., Taccari, F., Milozzi, E., Posteraro, B., Sanguinetti, M., Cauda, R., et al. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2527-2 · Cited by 24
“Mortality rates due to candidemia are very high, especially in patients admitted to ICUs, ranging from 40 % to 60 % [5, 6], even though data on attributable mortality are controversial [7, 8].”
Moragues-Solanas, L., Le-Viet, T., McSorley, E., Halford, C., Lockhart, D. S., Aydin, A., Kay, G. L., Elumogo, N., Mullen, W. H., O’Grady, J., et al. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01835-5 · Cited by 24
Chakravart, S., & Haleagraha, N. (2010) · Microbiology Journal · doi:10.3923/mj.2011.1.7 · Cited by 25
Evaluation of Human Body Fluids for the Diagnosis of Fungal Infections
Badiee, P. (2013) · BioMed Research International · doi:10.1155/2013/698325 · Cited by 23
Xiao, M., Wang, H., Lü, J., Chen, S. C.-A., Kong, F., Ma, X., & Xu, Y. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00246-14 · Cited by 22
Lawson, S., Arumugam, N., Almansour, A. I., Kumar, R. S., & Thangamani, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103865 · Cited by 25
Pratikaki, M. E., Platsouka, E. D., Sotiropoulou, C., Douka, E., Paramythiotou, E., Kaltsas, P., Kotanidou, A. N., Paniara, O., Roussos, C., & Routsi, C. (2011) · Mycoses · doi:10.1111/j.1439-0507.2009.01787.x · Cited by 27
The involvement of the Candida glabrata trehalase enzymes in stress resistance and gut colonization
Ende, M. V., Timmermans, B., Vanreppelen, G., Siscar-Lewin, S., Fischer, D., Wijnants, S., Romero, C. L., Yazdani, S., Rogiers, O., Demuyser, L., et al. (2021) · Virulence · doi:10.1080/21505594.2020.1868825 · Cited by 23
“Candida species are among the most frequently isolated human fungi, with a mortality rate of up to 50% [1,3,4].”
BackgroundChoy, A. M., & Freedberg, D. E. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820939447 · Cited by 24
Kumar, A., & Kethireddy, S. (2010) · Yearbook of Critical Care Medicine · doi:10.1016/s0734-3299(09)79335-9 · Cited by 22
Impact of infectious diseases consultation on the outcome of patients with bacteraemia
Jiménez-Aguilar, P., López-Cortés, L. E., & Rodríguez‐Baño, J. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119893576 · Cited by 20
Viscoli, C., Bassetti, M., Castagnola, E., Cesaro, S., Menichetti, F., Ratto, S., Tascini, C., & Giacobbe, D. R. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0725-7 · Cited by 21
“Background Candidemia and other forms of invasive candidiasis (IC) are a major cause of morbidity and mortality [1-7].”
BackgroundThe Diagnostic and Therapeutic Approach to Fungal Infections in Critical Care Settings
Zaragoza, R., & Pemán, J. (2008) · Cited by 21
Pitarch, A., Nombela, C., & Gil, C. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200601036 · Cited by 22
Won, E. J., Choi, M. J., Jeong, S. H., Kim, D., Shin, K. S., Shin, J. H., Kim, Y. R., Kim, H. S., Kim, Y. A., Uh, Y., et al. (2022) · Journal of Fungi · doi:10.3390/jof8100996 · Cited by 24
“Moreover, knowledge of the rank order of occurrence and resistance profiles of various Candida species causing BSIs is important to establish empirical treatment protocols [6,10,12].”
BackgroundMortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis
Colaneri, M., Giusti, E. M., Genovese, C., Galli, L., Lombardi, A., & Gori, A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad358 · Cited by 24
Serum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia
Abe, M., Kimura, M., Araoka, H., Taniguchi, S., & Yoneyama, A. (2014) · Medical Mycology · doi:10.1093/mmy/myu066 · Cited by 19
“However, establishing a diagnosis proves to be very difficult, and culture-based results are often delayed [15–17].”
BackgroundCateau, E., Cognée, A.-S., Tran, T. C., Vallade, E., Garcia, M., Belaz, S., Kauffmann‐Lacroix, C., & Rodier, M. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.12.012 · Cited by 21
“Fungemia has a major impact on patient outcome and is associated with high mortality (Chi et al., 2011; Falagas et al., 2006; Holley et al., 2009; Morgan et al., 2005).”
BackgroundPemán, J., & Zaragoza, R. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.128 · Cited by 21
Systematic clinical management of patients with candidemia improves survival
Murri, R., Giovannenze, F., Camici, M., Torelli, R., Ventura, G., Scoppettuolo, G., Sanguinetti, M., Cauda, R., & Fantoni, M. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.03.011 · Cited by 21
Murri, R., Camici, M., Posteraro, B., Giovannenze, F., Taccari, F., Ventura, G., Scoppettuolo, G., Sanguinetti, M., Cauda, R., & Fantoni, M. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s181489 · Cited by 20
Benoist, H., Rodier, S., Blanchardière, A. D. L., Bonhomme, J., Cormier, H., Thibon, P., & Saint‐Lorant, G. (2019) · Infection · doi:10.1007/s15010-018-01264-4 · Cited by 18
Lee, Y., Kim, D. Y., Kim, Y. J., Park, K., & Lee, M. S. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.08.018 · Cited by 18
Otto, C. C., & Babady, N. E. (2023) · Mycopathologia · doi:10.1007/s11046-023-00765-7 · Cited by 21
Manjunath, V., Vidya, G. S., Sharma, A. K., Prakash, M. R., & Murugesh (2012) · Cited by 17
Antifungal resistance: more research needed
Barnes, R. A., Gow, N. A. R., Denning, D. W., May, R. C., & Haynes, K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61861-4 · Cited by 17
Lim, H. J., Choi, M. J., Byun, S. A., Won, E. J., Park, J.-H., Choi, Y. J., Choi, H., Choi, H.-W., Kee, S., Kim, S. H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050515 · Cited by 19
“Candida bloodstream infections (BSIs) are the most common nosocomial fungal infections and are associated with high rates of mortality [1,2].”
BackgroundHacia el diagnóstico temprano de la candidiasis invasora en el paciente crítico
Pemán, J., & Zaragoza, R. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.03.002 · Cited by 21
Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update
Smith, W. J., Drew, R. H., & Perfect, J. R. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.7.2.165 · Cited by 18
G1 and S phase arrest in Candida albicans induces filamentous growth via distinct mechanisms
Chen, C., Zeng, G., & Wang, Y. (2018) · Molecular Microbiology · doi:10.1111/mmi.14097 · Cited by 17
“Invasive Candida infections are associated with high mortality rates ranging from 35 to 67% and significant healthcare costs and burden (Wilson et al., 2002; Falagas et al., 2006; Kett et al., 2011).”
Backgroundon behalf of GISA/FADOI Candida Study Group, Sozio, E., Pieralli, F., Azzini, A. M., Tintori, G., Demma, F., Furneri, G., Sbrana, F., Bertolino, G., Fortunato, S., et al. (2018) · Infection · doi:10.1007/s15010-018-1162-0 · Cited by 16
Suh, J. W., Kim, M. J., & Kim, J. H. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1959052 · Cited by 15
Kamysz, E., Simonetti, O., Cirioni, O., Arzeni, D., Ganzetti, G., Campanati, A., Giacometti, A., Gabrielli, E., Silvestri, C., Kamysz, W., et al. (2010) · Peptides · doi:10.1016/j.peptides.2010.10.022 · Cited by 15
Antifungal management in cancer patients
Staber, P. B., Langner, S., Dornbusch, H. J., & Neumeister, P. (2007) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-007-0466-y · Cited by 17
Factors influencing voriconazole plasma level in intensive care patients
Hinze, C. A., Fuge, J., Grote-Koska, D., Brand, K., Slevogt, H., Cornberg, M., Simon, S., Joean, O., Welte, T., & Rademacher, J. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae045 · Cited by 14
Clinical Aspects of Invasive Candidiasis in Critically Ill Patients
Pennisi, M. A., & Antonelli, M. M. (2009) · Drugs · doi:10.2165/11315590-000000000-00000 · Cited by 16
“Data from matched-cohort and casecontrol studies indicate that the mortality attributable to candidaemia ranges from 5% to a dramatic 71%.([5-8]) The permanence of a CVC and inadequate initial fluconazole dosing are factors associated with increased hospital mortality.”
MethodAn outbreak of Candida parapsilosis fungemia among preterm infants
Guo, W., Gu, H. F., Zhang, H. G., Chen, S. B., Wang, J. Q., Geng, S., Li, L., Liu, P., Liu, X., Ji, Y., et al. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.23.13 · Cited by 16
Design and use of Candida scores at the intensive care unit
Kratzer, C., Graninger, W., Lassnigg, A. M., & Presterl, E. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01953.x · Cited by 18
Métodos diagnósticos en candidemia: una revisión sistemática de la literatura con meta-análisis
Cortés, J. A., Mejía, A. C., Luis Eduardo Cediel, T., & Castillo, J. S. (2011) · Revista chilena de infectología · doi:10.4067/s0716-10182011000600006 · Cited by 17
Synergistic Growth Inhibition of Herbal Plant Extract Combinations against Candida albicans
Jeemin, Y. O. O. N., & Kim, T. (2023) · Journal of the Korean Wood Science and Technology · doi:10.5658/wood.2023.51.2.145 · Cited by 14
“and such infections lead to prolonged hospitalization and high mortality (Falagas et al. , 2006).”
Samonis, G., Galanakis, E., Ntaoukakis, M., Sarchianaki, E., Spathopoulou, T., Dimopoulou, D., Kofteridis, D. P., & Maraki, S. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02212.x · Cited by 13
Molecular epidemiology of late recurrent candidaemia—a population-based study in Iceland
Ásmundsdóttir, L. R., Erlendsdóttir, H., Gísladóttir, A., & Gottfreðsson, M. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03595.x · Cited by 12
“Candidaemia has a major impact on patient outcome, in terms of both morbidity and mortality [9,10] and increased length of hospital stay [11,12].”
BackgroundCandidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients
Ferrada, M. A., Quartin, A. A., Kett, D. H., & Morris, M. I. (2013) · BMC Anesthesiology · doi:10.1186/1471-2253-13-37 · Cited by 12
“Increasing attributable mortality from candidemia has prompted research into the role of early diagnosis and treatment in improving outcomes [3,5,6].”
BackgroundMarchena‐Gómez, J., Saez‐Guzman, T., Hemmersbach‐Miller, M., Martel, A. C., León, V. M., Benítez, A. B., & Acosta‐Mérida, M. A. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0120-5 · Cited by 13
“[21] recently published a systematic review of matched cohorts and case-control studies to illustrate the mortality associated with candidemia.”
BackgroundKřenová, Z., Pavelka, Z., Lokaj, P., Skotáková, J., Kocmanová, I., Teyschl, O., Křen, L., Múdrý, P., & Štěrba, J. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181cb49a8 · Cited by 11
“A systematic review of case-control studies reported mortality rates attributable to candidaemia ranging from 5% in a US intensive care unit to 71% in liver-transplant recipients.(3) Liposomal amphotericin B and caspofungin remain the gold standard for empirical therapy of neutropenic patients, but azole antifungals (…”
BackgroundDiversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates
Andersen, K.-M., Kristoffersen, A. K., Ingebretsen, A., Vikholt, K. J., Örtengren, U. T., Olsen, I., Enersen, M., & Gaustad, P. (2016) · Journal of Oral Microbiology · doi:10.3402/jom.v8.29849 · Cited by 12
“glabrata clinical isolates (n 15) FL (2), VO (5)”
BackgroundIdentification of Candida species using CHROM agar.
Khadka, S., Regmi, P., Giri, S., Shah, P. K., & Mishra, S. K. (2016) · International Journal of Medicine and Biomedical Sciences · doi:10.55530/ijmbiosnepal.v1i4.15 · Cited by 12
“Candida species have been found to be one of the most common pathogens causing up to 15% of nosocomial bloodstream infection and mortality rate ranging from 5-71% (21).”
BackgroundSaghrouni, F., Bougmiza, I. M., Abdeljelil, J. B., Yacoub, A., Khammari, I., Fathallah, A., Mtiraoui, A., & Saïd, M. B. (2011) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2011.04.004 · Cited by 13
Yu, S. N., Hong, S. I., Park, J. W., Jeon, M. H., & Cho, O. (2025) · Journal of Fungi · doi:10.3390/jof11030217 · Cited by 13
“Candida , one of the most important causative agents of bloodstream infections (BSIs) in hospitals, is associated with high morbidity and mortality [1,2].”
Epidemiology and Outcomes of Candidemia in a Referral Center in Tehran.
Salehi, M., Ghomi, Z., Mirshahi, R., Manshadi, S. A. D., & Rezahosseini, O. (2019) · PubMed Central · doi:10.22088/cjim.10.1.73 · Cited by 11
“Although most patients with candidemia are from the intensive care units (ICUs), this infection can also occur in other hospital wards (10) and is known as one of the most common causes of mortality and morbidity in healthcare centers, with a mortality rate of nearly 71% (10-12).”
BackgroundPrevalence of Candida bloodstream isolates from patients in two hospitals in Vietnam
Bac, N. D., Le, T., Quang, L. B., Lực, N. K., Thi, T., Nagi, M., Yoshitsugu, M., Hà, H. T. T., Anh, Đ. Đ., Đỗ, Q., et al. (2019) · Iranian Journal of Microbiology · doi:10.18502/ijm.v11i2.1071 · Cited by 17
“Nosocomial bloodstream infections due to Candida species are associated with a mortality rate of 5% to 71% (2, 3).”
BackgroundEchinocandins in invasive candidiasis
Simon, J., Sun, H., Leong, H. N., Barez, M. Y., Huang, P., Talwar, D., Wang, J.-H., Mansor, M. M., Wahjuprajitno, B., Patel, A. K., et al. (2013) · Mycoses · doi:10.1111/myc.12085 · Cited by 12
Pang, Y., Ip, M., & You, J. H. S. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2796-4 · Cited by 12
Cambios clínicos y epidemiológicos de candidemias en pacientes adultos desde 2000 a 2013
Sin, L., Legarraga, P., García, P., González, T. C., & Ricardo Rabagliati, B. (2017) · Revista chilena de infectología · doi:10.4067/s0716-10182017000100003 · Cited by 18
Clinical Sensitivity of the (1–3)-β-D-glucan Test for Predicting Candidemia
Lee, Y. W., Lim, S. Y., Jin, S., Park, H. J., Sung, H., Kim, M., Bae, S., Jung, J., Kim, M. J., Kim, S., et al. (2023) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.43.4.381 · Cited by 10
“Candidemia is a major cause of hospital-acquired infections and mortality [1-3].”
Healthcare‐associated candidemia—A distinct entity?
Gulia, J., Aryal, S., Saadlla, H., & Shorr, A. F. (2010) · Journal of Hospital Medicine · doi:10.1002/jhm.652 · Cited by 9
Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution
Liew, Y. X., Teo, J. Q.-M., Too, I. A.-L., Ngan, C. C. L., Tan, A. L., Chlebicki, M. P., Kwa, A. L., & Lee, W. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0997-6 · Cited by 11
“Background Invasive candidiasis (IC) in critically ill patients is associated with high mortality and morbidity [1, 2].”
BackgroundPagès, A., Iriart, X., Molinier, L., Georges, B., Berry, A., Massip, P., & Juillard‐Condat, B. (2017) · Value in Health · doi:10.1016/j.jval.2017.06.009 · Cited by 9
Patterson, L., McMullan, R., & Harrison, D. A. (2019) · Mycoses · doi:10.1111/myc.12956 · Cited by 12
Ghojoghi, A., Erfaninejad, M., Ahmadpour, E., Nazar, E., Barac, A. M., & Fatahinia, M. (2022) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.356992 · Cited by 11
Grüger, T., Mörler, C., Schnitzler, N., Brandenburg, K., Nidermajer, S., Horré, R., & Zündorf, J. (2008) · Medical Mycology · doi:10.1080/13693780802017535 · Cited by 8
Kahramanmaras Afsin Devlet Hastanesi, I. H. V. K. M. K., Kolak, C. C., Daloğlu, A. E., Özhak, B., Öğünç, D., & Günseren, F. (2020) · Klimik Dergisi/Klimik Journal · doi:10.5152/kd.2019.71 · Cited by 10
Devrim, İ., Topal, S., Ceylan, G., Oruç, Y., Gülfidan, G., Ayhan, F. Y., Bayram, N., & Ağın, H. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101277 · Cited by 12
Viale, P., Mirandola, S., Natalini, C., Esposti, L. D., Dovizio, M., Veronesi, C., Forcina, G., Navalesi, P., & Boscolo, A. (2024) · Mycoses · doi:10.1111/myc.13779 · Cited by 8
Metadata
- Authors
- Falagas, M. E., Apostolou, K. E., & Pappas, V. D.
- Affiliations
- Tufts University (US)
- Alfa Institute of Biomedical Sciences (GR)
- Corresponding author
- Falagas, M. E.
- ORCID
- Falagas, M. E.
- Venue
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2006-06-14
- Volume
- 25
- Issue
- 7
- Pages
- 419-425
- ISSN
- 0934-9723 (ISSN-L)
- 1435-4373
- OpenAlex
- W2089115810
- Semantic Scholar
- aeb27cd38dec2cc6bc8a111d9effed9e8eb45139
- Cited by
- 294
- References
- 21
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 10 · 2023: 8 · 2022: 11 · 2021: 12 · 2020: 14 · 2019: 13 · 2018: 11 · 2017: 13 · 2016: 22 · 2015: 21 · 2014: 20 · 2013: 16 · 2012: 17
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Microbiology & Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, attributable mortality, invasive fungal infections, length of hospital stay, hospital costs, intensive care unit patients, transplant recipients, comorbidities
- MeSH terms
- Adult, Candida, Candidiasis, Child, Hospitalization, Humans, Length of Stay, Cohort Studies, Case-Control Studies, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.